What We Monitor for Biotechnology Companies
BLA pathway updates
Biosimilar interchangeability guidance
CBER policy shifts
Cell & gene therapy frameworks
Regenerative medicine pathways
Clinical trial design expectations
Manufacturing (biologics-specific) guidance
Post-market biosimilar monitoring
Expedited program eligibility shifts
Decisions This Intelligence Affects
Regulatory Strategy
- • Pathway selection (351(a) vs 351(k))
- • Expedited designation timing
- • Pre-BLA meeting strategy
- • Comparability protocol decisions
CMC & Manufacturing
- • Process validation approach
- • Analytical method expectations
- • Facility design decisions
- • Tech transfer timing
Clinical Development
- • Trial design alignment with FDA expectations
- • Endpoint selection rationale
- • Adaptive design considerations
- • Real-world evidence integration
Executive & Investor Relations
- • Pipeline risk communication
- • Regulatory milestone credibility
- • Competitive landscape shifts
- • Partnership due diligence
How Biotech Teams Use This Intelligence
Navigate Expedited Pathways
Understand Breakthrough, Fast Track, and RMAT eligibility shifts
Optimize Biosimilar Strategy
Track interchangeability guidance and switching study expectations
Accelerate CMC Decisions
Anticipate comparability and manufacturing guidance changes
Reduce Clinical Risk
Align trial design with evolving FDA endpoint expectations
Strengthen Board Communications
Cite regulatory intelligence in pipeline risk discussions
Support Due Diligence
Inform M&A and partnership decisions with regulatory context